White crystalline powder
GLYCAMIL/Ammoniumglycynhizinato/glycyrrhizic acid monoammonium salt/ammonium glycyrrhizinate/Glycyrrhizin Monoammonium Salt Hydrate/Glycyrrhizic Acid Monoammonium Salt Hydrate/(3β)-30-Hydroxy-11,30-dioxoolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-α-D-glucopyranosiduronic acid diammoniate/GLYCYRRHIZICAMMONIUM/Magnasweet/ammoniate/Monoammonium Glycyrrhizinate Hydrate/Glycyrrhizate monoammonium/Glycyrrhizin ammonium/Olean-12-en-30-oic acid, 3-[(2-O-β-D-glucopyranuronosyl-α-D-glucopyranuronosyl)oxy]-11-oxo-, diammonium salt, (3β)-/Glycyrrhiz/AMMONIUMGLYCYRRHIZIN/Ammonium glycyrrhizate/GLYCYRRHIZIC ACID,NH4/ammoniumglycyrrhizate/Monoammoniumglycyrrhizinate/Glycyrrhizic acid monoammonium salt trihydrate/Olean-12-en-30-oic acid, 3-[(2-O-β-D-glucopyranuronosyl-α-D-glucopyranuronosyl)oxy]-11-oxo-, ammonium salt, (3β)-/glycyrram
971.4ºC at 760mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:53956-04-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
The objective of this study was to evaluate the cardioprotective effect of herbal bioactive compound ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy, in experimental animals.
MATERIALS AND METHODS:
Ammonium glycyrrhizinate (50, 100, 200 mg/kg, p.o.) was administered for four weeks in albino rats. Cardiomyopathy was induced with a dose of 2.5 mg/kg i.p. of doxorubicin on 1(th), 7(th), 14(th), 21(th), 28(th) day in the experimental animals. At the end of the experiment, on 29(th) day, serum and heart tissues were collected and hemodynamic, biochemical and histopathological studies were carried out.
Administration of doxorubicin in normal rats showed significant (P < 0.001) changes in body weight, feed intake, urine output, hemodynamic parameters like (blood pressure, heart rate, cardiac output) and in lipid profile (cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, very low density lipoprotein) indicating cardiomyopathy symptoms. Animals treated with ammonium glycyrrhizinate significantly (P < 0.05) decreased triglyceride, cholesterol, low density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels. Moreover, high density lipoprotein (HDL) levels increased in rats treated with ammonium glycyrrhizinate as compared with the normal group. CONCLUSION: Ammonium glycyrrhizinate is effective in controlling serum lipid profile and cardiac complications in experimentally induced cardiomyopathy in animals.
Ammonium glycyrrhizinate; cardiac failure; cardiomyopathy; doxorubicin
Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals.
Garg M1, Singhal T1, Sharma H1.
Monoammonium glycyrrhizinate hydrate has various pharmacological actions such as anti-inflammatory, antiallergic, antigastriculcer, and antihepatitis activities.